ciprofloxacin has been researched along with Pneumonia, Pneumococcal in 25 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Pneumonia, Pneumococcal: A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "P." | 1.42 | Bloodstream bacterial infection among outpatient children with acute febrile illness in north-eastern Tanzania. ( Butichi, A; Lemnge, M; Lushino, P; Lusingu, J; Mahende, C; Mmbando, B; Ngasala, B; Premji, Z, 2015) |
| "During the last decade some studies have shown that the area under the curve (AUC)/MIC ratio is the pharmacodynamic index that best predicts the efficacies of quinolones, while other studies suggest that the predictive value of the peak concentration/MIC (peak/MIC) ratio is superior to the AUC/MIC ratio in explaining clinical and microbiological outcomes." | 1.32 | Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios. ( Fraschini, F; Mattina, R; Mouton, JW; Scaglione, F, 2003) |
| " The pharmacokinetic profiles also reflected the effectiveness of GFLX." | 1.32 | Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae. ( Fukuda, Y; Hirakata, Y; Kadota, J; Kohno, S; Miyazaki, Y; Murata, I; Tashiro, T; Tomono, K; Tsukamoto, K; Yanagihara, K, 2004) |
| "We looked for associations between pharmacokinetic (Pk) and pharmacodynamic (Pd) parameters of ciprofloxacin (CPFX) and sparfloxacin (SPFX) and the in vivo efficacy of these antimicrobials in an immunocompetent mouse model of severe Streptococcus pneumoniae pneumonia." | 1.30 | Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. ( Azoulay-Dupuis, E; Bédos, JP; Moine, P; Muffat-Joly, M; Pocidalo, JJ; Vallée, E; Veber, B, 1998) |
| "Ciprofloxacin was not inactivated at sites of infection." | 1.28 | Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy. ( Azoulay-Dupuis, E; Bauchet, J; Pocidalo, JJ; Vallée, E, 1992) |
| " The terminal half-life was 4." | 1.28 | Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. ( Arich, C; Beziau, H; Bressolle, F; Fabre, D; Galtier, M; Gomeni, R; Lemesle, F, 1991) |
| "Treatment with ofloxacin and ciprofloxacin at 50 mg/kg 18 h after infection did not significantly increase survival rates compared with those of untreated controls." | 1.28 | Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. ( Azoulay-Dupuis, E; Bedos, JP; Hardy, DJ; Pocidalo, JJ; Swanson, RN; Vallée, E, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 13 (52.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 1 (4.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mahende, C | 1 |
| Ngasala, B | 1 |
| Lusingu, J | 1 |
| Butichi, A | 1 |
| Lushino, P | 1 |
| Lemnge, M | 1 |
| Mmbando, B | 1 |
| Premji, Z | 1 |
| Ellbogen, MH | 1 |
| Olsen, KM | 1 |
| Gentry-Nielsen, MJ | 1 |
| Preheim, LC | 1 |
| Bello, S | 1 |
| Torres, A | 1 |
| García-Olmos, M | 1 |
| Parra, A | 1 |
| García-Calvo, G | 1 |
| Ponte, C | 1 |
| Giménez, MJ | 1 |
| Aguilar, L | 1 |
| Soriano, F | 1 |
| Scaglione, F | 1 |
| Mouton, JW | 1 |
| Mattina, R | 1 |
| Fraschini, F | 1 |
| Otsu, Y | 1 |
| Yanagihara, K | 2 |
| Fukuda, Y | 2 |
| Miyazaki, Y | 2 |
| Tsukamoto, K | 2 |
| Hirakata, Y | 2 |
| Tomono, K | 2 |
| Kadota, J | 2 |
| Tashiro, T | 2 |
| Murata, I | 2 |
| Kohno, S | 2 |
| Sahm, DF | 1 |
| Thornsberry, C | 1 |
| Jones, ME | 1 |
| Karlowsky, JA | 1 |
| Pletz, MW | 1 |
| McGee, L | 1 |
| Burkhardt, O | 1 |
| Lode, H | 1 |
| Klugman, KP | 1 |
| Hayashi, K | 1 |
| Kadowaki, SE | 1 |
| Takei, M | 1 |
| Fukuda, H | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| Gootz, TD | 1 |
| Zaniewski, R | 1 |
| Haskell, S | 1 |
| Schmieder, B | 1 |
| Tankovic, J | 1 |
| Girard, D | 1 |
| Courvalin, P | 1 |
| Polzer, RJ | 1 |
| Bédos, JP | 3 |
| Azoulay-Dupuis, E | 4 |
| Moine, P | 1 |
| Muffat-Joly, M | 1 |
| Veber, B | 2 |
| Pocidalo, JJ | 4 |
| Vallée, E | 4 |
| Tillotson, G | 1 |
| Zhao, X | 1 |
| Drlica, K | 1 |
| Bauchet, J | 2 |
| Nahass, RG | 1 |
| Fabre, D | 1 |
| Bressolle, F | 1 |
| Gomeni, R | 1 |
| Arich, C | 1 |
| Lemesle, F | 1 |
| Beziau, H | 1 |
| Galtier, M | 1 |
| Thys, JP | 1 |
| Jacobs, F | 1 |
| Byl, B | 1 |
| Hardy, DJ | 1 |
| Swanson, RN | 1 |
| Mouton, Y | 1 |
| Beuscart, C | 1 |
| Leroy, O | 1 |
| Ajana, F | 1 |
| Charrel, J | 1 |
| Pérez-Trallero, E | 1 |
| Garcia-Arenzana, JM | 1 |
| Jimenez, JA | 1 |
| Peris, A | 1 |
| Frieden, TR | 1 |
| Mangi, RJ | 1 |
| Gordon, JJ | 1 |
| Kauffman, CA | 1 |
| Cooper, B | 1 |
| Lawlor, M | 1 |
2 reviews available for ciprofloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Humans; | 2001 |
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
2 trials available for ciprofloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.
Topics: Anti-Infective Agents; Bronchitis; Ciprofloxacin; Drug Therapy, Combination; Enoxacin; Humans; Oflox | 1991 |
[Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia].
Topics: Adult; Amoxicillin; Ciprofloxacin; Clavulanic Acids; Erythromycin; Female; Humans; Male; Pneumonia, | 1991 |
22 other studies available for ciprofloxacin and Pneumonia, Pneumococcal
| Article | Year |
|---|---|
Bloodstream bacterial infection among outpatient children with acute febrile illness in north-eastern Tanzania.
Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Child; Child, Preschool; Chlorampheni | 2015 |
Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia.
Topics: Animals; Bronchoalveolar Lavage Fluid; Ceftriaxone; Ciprofloxacin; Colony Count, Microbial; Disease | 2003 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciproflo | 2003 |
Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; | 2003 |
Pharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratios.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Colony Count, Microbial; Dose-Respo | 2003 |
In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Lung; Male; Mice; Mic | 2003 |
Factors influencing fluoroquinolone resistance.
Topics: Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Microbia | 2003 |
Pharmacodynamics and bactericidal activity of gatifloxacin in experimental pneumonia caused by penicillin-resistant Streptococcus pneumoniae.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Eva | 2004 |
Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.
Topics: Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Therapy, Combination; F | 2005 |
Efficacy of quinolones against secondary pneumococcal pneumonia after influenza virus infection in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Lung; Mice; M | 2006 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Dr | 1996 |
Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Female; Fluoroquinolones; Mice; Mice, Inbred C57BL; M | 1998 |
Kinetic disposition of temafloxacin and ciprofloxacin in a murine model of pneumococcal pneumonia. Relevance for drug efficacy.
Topics: Animals; Anti-Infective Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Female; Fluoroq | 1992 |
In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Female; Fluoroquinolones; Leu | 1992 |
Advertising and indications for drug use.
Topics: Advertising; Aged; Ciprofloxacin; Female; Humans; Pneumonia, Pneumococcal | 1992 |
Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bronchi; Chromatography, High Pressure Liquid; Ciprof | 1991 |
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Erythromycin; Fe | 1991 |
Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Humans; M | 1990 |
Inappropriate use of oral ciprofloxacin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cellulitis; Ciprofloxacin; Drug Utilization; F | 1990 |
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumonia; Pneumonia, Pneumococcal; Pseudomonas Infections | 1990 |
Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia.
Topics: Ciprofloxacin; Humans; Male; Middle Aged; Pneumococcal Infections; Pneumonia, Pneumococcal; Sepsis | 1989 |